Uncategorized Archives - Page 3 of 134

TuesdayFeb 25, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research

One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts. Calidi’s improved financial footing reassures investors and allows the company to focus on achieving key milestones in its research pipeline. The company has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious AACR annual meeting in April 2025. Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented…

TuesdayFeb 25, 2025 10:45 am

How Adageis Simplifies Value-Based Care, Boosting Revenue for Healthcare Providers

Adageis streamlines complex insurance contracts, helping providers maximize reimbursements. The company’s AI-driven solutions reduce administrative burden, freeing up time for patient care. Seamless integration with nearly 100 EHR systems ensures a smooth transition to value-based care models. The company’s fintech approach enhances financial performance, with providers seeing up to $75,000 in additional revenue. Adageis projects significant growth, expecting to cover 580,000 patient lives by mid-2025. Healthcare is shifting toward value-based care, where providers are reimbursed for patient outcomes rather than the number of procedures performed. While the model promises higher-quality care at lower costs, it also introduces complex reimbursement structures…

TuesdayFeb 25, 2025 10:00 am

2025 eCommerce Trends That Could Be Game Changers for Your Online Business

The worldwide e-commerce market is predicted to expand by 7.8% and reach a market value of $6.5 trillion by the end of this year. As an e-commerce operator, it is in your best interest to leverage the emerging trends so that your business can claim its fair share of this expanding market. We discuss some of those trends below. Social Commerce This is one big trend to watch if you are into e-commerce. Social media as well as other digital channels are the hallmarks in this trend. The concept allows transactions to happen easily between businesses and their target clientele.…

MondayFeb 24, 2025 1:00 pm

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

According to the American Cancer Society, cancer is the second leading cause of death globally. Oncology drugs are a cornerstone of modern cancer treatment. Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments. Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of research and development, offering hope for millions of patients worldwide.…

FridayFeb 21, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors

As cancer numbers grow, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving patient outcomes. Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells while activating the body’s own immune system to attack the tumor. The company’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors. Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and…

FridayFeb 21, 2025 10:00 am

How Adageis’ ProActive Care Approach Puts Patients First While Boosting Provider Revenue

Shifting to value-based care improves patient outcomes and cost-effective provider efficiency. Adageis’ ProActive Care shifts focus from reactive treatment to preventive, patient-centered care, with AI-driven analytics identifying high-risk patients and addressing care gaps. Patients receive more personalized, effective treatment, rather than a volume treatment driven approach. Better patient outcomes lead to reduced hospitalizations and cost savings, while increased cost monitoring and efficiency for providers supports increased revenue and net income potential. For many patients, the American healthcare system often feels rushed, transactional and fragmented. Doctors have limited time, and treatment decisions can be driven by billing structures rather than patient…

ThursdayFeb 20, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focused on Advancing Stem Cell-Based Research Amid Rising Cancer Concerns

Rising cancer numbers indicate urgent need for advancements in cancer research, and stem cell research is rising to meet the challenge. Stem cells are being explored not only as a tool to regenerate damaged tissues but also as a delivery vehicle for innovative cancer treatments. Calidi Biotherapeutics stands at the forefront of integrating stem cell technology into oncology. As 2025 approaches, cancer continues to be one of the most significant global health challenges. Projections indicate a sharp increase in cancer diagnoses, with new cases in 2024 expected to surpass 2 million annually in the United States for the first time.…

TuesdayFeb 11, 2025 1:35 pm

How Adageis Uses Data to Drive Value-Based Care Adoption and Boost Revenue for Healthcare Providers

Value-based care models prioritize proactive, high-quality patient care, and, if done correctly, can significantly enhance financial outcomes. Healthcare organizations adopting a value-based care approach can see increased revenue through efficiency, reduced hospitalizations and incentive payments. Adageis provides AI-driven solutions that help providers transition to and optimize value-based care models. The company’s data analytics features play a critical role in identifying high-risk patients, closing care gaps and controlling costs. Healthcare is undergoing a major transformation as more organizations shift from fee-for-service to value-based care. Under value-based care models, providers are reimbursed based on patient outcomes rather than the volume of services…

FridayJan 31, 2025 10:00 am

Adageis Leveraging Data-Driven Solutions to Advance Value-Based Care and Drive Financial Performance

Adageis, with its AI-centric software ProActive Care Platform, supports healthcare providers in making the important shift toward effective value-based care models. Significantly, the company’s advanced patient healthcare data solutions are designed for seamless implementation across ACOs, CINs, and IPAs, integrating with existing electronic health records (“EHRs”) to identify high-risk patients and care gaps. The company helps providers navigate the financial incentives tied to value-based care by tracking performance metrics, as its Patented Risk Engine (“PRE”) enables proactive interventions, reducing costs and improving patient outcomes. Healthcare providers are under increasing pressure to transition from fee-for-service models to value-based care, where reimbursement…

ThursdayJan 30, 2025 10:00 am

Adageis is at the Forefront of AI Implementation in Healthcare as Industry Shifts from General Intelligence to Targeted Impact, Tools Driving Higher Reimbursements

Healthcare is transitioning attention from general AI to targeted applications like patient risk assessment and workflow optimization to drive higher reimbursements. Adageis’s ProActive Care Platform addresses critical targeted areas like tracking revenue and performance from providing high-quality care. AI tools like Adageis’ patented Risk Engine enable proactive interventions, reducing costs and improving patient outcomes while increasing overall revenue. The company’s platform integrates seamlessly with major electronic health records (“EHR”) systems, in an easy-to-use app for providers. Artificial intelligence is reshaping healthcare, moving from ambitious goals of Artificial General Intelligence (“AGI”) to more targeted, high-impact applications. This transition aligns with the practical demands…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research

How Adageis Simplifies Value-Based Care, Boosting Revenue for Healthcare Providers

2025 eCommerce Trends That Could Be Game Changers for Your Online Business

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors

How Adageis’ ProActive Care Approach Puts Patients First While Boosting Provider Revenue

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focused on Advancing Stem Cell-Based Research Amid Rising Cancer Concerns

How Adageis Uses Data to Drive Value-Based Care Adoption and Boost Revenue for Healthcare Providers

Adageis Leveraging Data-Driven Solutions to Advance Value-Based Care and Drive Financial Performance

Adageis is at the Forefront of AI Implementation in Healthcare as Industry Shifts from General Intelligence to Targeted Impact, Tools Driving Higher Reimbursements

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search